In contrast, the PMILs showed little size change over 2.5 months of storage, which may be attributed to the solvent protection by the lipid envelope to slow degradation of the polymeric core nanoparticle.
Supplementary Figure 5.
Electron microscopy particle counts, lamellarity and PMIL structure following NIR photoirradiation.
Supplementary Figure 5⎪Cryo-electron microscopy (cryo-EM), negative stain transmission electron microscopy (TEM) and dynamic light scattering (DLS) were used to examine PMIL size and structure before and after NIR photoinduced drug release. a, Exemplary cryo-EM image (41,000 ×) of a PMIL sample. In the enlarged image of the boxed region (right), arrows (white) and arrowheads (black) indicate liposome bilayers and unencapsulated NP [XL184] , respectively; open (red) and closed (green) circles indicate empty and NP[XL184]-encapsulating liposomes; and, numbers indicate liposome lamellarity. Scale bars, 100 nm. b, Exemplary projection along a single axis from a cryo-EM tomogram (2D); and, two views of the corresponding tomographic reconstruction (3D) of a PMIL with an adjacent, unencapsulated NP[XL184] (i, black arrowheads)-that appears encapsulated in 2D-and an encapsulated NP[XL184] not resolved in the 2D projection (ii, white arrowheads). Scale bar, 100 nm. c, Quantification of NP[XL184] encapsulation within liposomes (n = 3,400 objects from 12 tomograms of a single PMIL preparation; 41,000 ×) as well as liposome counts for each lamellarity (ranging from 1 to 5; n = 739 liposomes from 7 images of a single PMIL preparation; 41,000 ×). Results are mean ± s.e.m. NP[XL184] counts were evaluated manually in the reconstructed tomograms (3D) over the entire sample depth. This approach avoids false positives due to unencapsulated NP[XL184] objects above and below liposomes. Note that a number of nanoparticle-and or lipid fragments appear at the air-water interface and were counted as a major population of unencapsulated NP[XL184] objects. d, DLS measurements do not indicate a change in overall size distribution following photoirradiation (37°C; 690 nm; 150 mW·cm −2 ) of PMILs in phosphate-buffered saline (n = 4 technical replicates). e, Exemplary negative stain TEM images of a PMIL sample before and after irradiation from which particle counts shown in Fig. 3d ,e were evaluated manually. The outer edge of the PMIL is visible prior to irradiation (0 J·cm −2 ; arrows indicate the lipid bilayer), but is not apparent following NIR photoirradiation (5, 50 or 100 J·cm 55 . The nanocell drug delivery system developed by Sengupta and colleagues introduced drug co-packaging with temporal control over drug release 43 . In the seminal study, nanocells were engineered to rapidly release a vascular disrupting agent from the lipid bilayer to promote vascular shutdown, followed by a slower release (after a lag of 30-90 h) of a chemotherapeutic agent from the core nanoparticles trapped within the tumour 43 . The nanocell co-delivery with temporal targeting of distinct tumour compartments enhanced the efficacy of the combination therapy and reduced toxic side-effects compared to coadministration of the individually packaged agents 43 .These gains were attributed to an enhanced payload and focused release of the chemotherapeutic agent within the tumour 43 . ThermoDox builds upon Doxil to enable pulsed-high intensity focused ultrasound-triggered release of doxorubicin from a heat-sensitive liposome 42, 52 and is presently in clinical trials for a variety of cancers (e.g., NCT00617981 and NCT00826085). Mayer and colleagues developed the CPX-351 liposome system to introduce prolonged maintenance of synergistic drug ratios 41, 54 and this approach is in clinical trials of acute myeloid leukemia and other hematologic cancers (e.g., NCT01696084). The US Food and Drug Administration (FDA) as well as the European Medicines Agency granted MM-398 orphan drug designation in 2011 for treatment of metastatic pancreatic cancer and MM-398 is presently in phase III clinical trials of metastatic pancreatic cancer (NCT01494506) and under FDA Priority Review.
Supplementary Note 2. Lipid peroxidation
56,57 as well as membrane permeabilization 4,22 and lysis 58 are known effects of photochemistry. The BPD released from the PMIL (Fig. 2f and Supplementary Fig. 4 ) is apparently no longer part of the bilayer structure and is able to pass through the dialysis membrane perhaps via serum exchange, lipid fragments and/or as free molecules (monomers and oligomers). Note that some serum components are larger than the dialysis pore size. However, the majority of serum components (~55% of total protein) are albumin proteins (~67 kDa), which are smaller than the 300 kDa molecular weight cut-off dialysis tubes used in the PMIL drug release experiments. Nevertheless, a few serum components will not pass through the dialysis membrane and other methods will need to be developed to quantify absolute drug serum exchange in future studies.
Supplementary Note 3.
Cryo-EM tomograms were quantified to estimate NP[XL184] encapsulation within liposomes in PMIL samples ( Supplementary Fig. 5 ). Quantification of multiple fields determined at least 20% of liposomes encapsulate one or more PLGA-PEG nanoparticles unambiguously visible by cryo-EM, and at least 20% of nanoparticles unambiguously visible by cryo-EM are encapsulated within liposomes. It is possible that the unencapsulated PLGA-PEG nanoparticles are coated with a lipid monolayer based on prior reports of lipid monolayer self-assembly onto PLGA nanoparticles 59, 60 . Such a lipid coating would be expected to also delay drug release 59 , to carry BPD and to support NIR photo-induced drug release. Note that a population of the PLGA-PEG nanoparticles (faint NP[XL184] particles in Fig. 3a) has insufficient electron density and contrast to be clearly visible when incorporated into liposomes. This is a fundamental limitation of this state-of-the-art approach to quantifying nanoparticle encapsulation and may underreport the encapsulation efficiency. Furthermore, a population of the unencapsulated NP[XL184] objects are adjacent to-and appear to be associated with-liposomes, such that they might also be co-delivered with the liposome. It is possible that development of a PMIL purification protocol to remove empty liposomes and unencapsualted NP[XL184] might improve efficacy. However, the data indicate light activated drug release even in the presence of the unencapsulated NP[XL184] supporting the possibility that this population contributes significantly to the therapy (via a lipid monolayer coating). Cryo-EM also revealed empty liposomes and multilamellar liposomes within the PMIL samples ( Fig. 3a and Supplementary Fig. 5a,c) . However, without nanoparticle loading and encapsulation, it is not possible to achieve the XL184 encapsulation efficiency into the PMIL achieved here. Encapsulating free XL184 into liposomes would be extremely inefficient-XL184 has very limited solubility in aqueous solutions ( <0.13-0.75 mg/mL; US Food and Drug Administration application number 203,756). That is, free XL184 would precipitate before it could be encapsulated efficiently into liposomes whereas the PLGA-PEG nanoparticle enables a XL184 loading efficiency of 50-60% (Fig. 2e) with a final concentration of ~57 mg/mL XL184. This level of XL184 loading exceeds the solubility limit of free XL184 by a factor of 75-400 and compares well to the loading efficiency of lipophilic BPD in liposomes (70-80%; Fig. 2e ). In regards to lamellarity, the mean lamellarity of liposomes within the PMIL sample is 1.36 ± 0.07 (mean ± s.d.), and 71% ± 4.6% (mean ± s.d.) of PMILs are unilamellar (lamellarity = 1; Methods and Supplementary Fig. 5c ). This agrees with prior reports that extrusion through a 50-200 nm pore results in unilamellar vesicles with the presence of residual multilamellar liposomes visible by cryo-EM 61 .
Supplementary Note 4. XL184 inhibits multiple receptor tyrosine kinases (RTKs). XL184 has potent activity towards MET (both wild-type and mutant; IC 50 = 1-15 nM) and VEGFR2 (35 pM), as well as its strong inhibition of VEGFR1, VEGFR3, RET, KIT, AXL, FLT3 and TIE2 (5-14 nM). In addition, XL184 has some activity against RON and PDGFRβ ( >100 nM) 39,62 (see also US Food and Drug Administration application number 203,756). XL184 has been proven to induce antiangiogenic (through VEGFR2 inhibition) and anti-invasive (through MET inhibition) effects 16 and to potentiate gemcitabine chemotherapy in preclinical models of pancreatic cancer 14, 24 . In addition to suppressing paracrine signaling to support tumour growth, XL184 also directly inhibits cancer cell intra-and autocrine cancer cell signaling pathways, including MET and VEGFR1 [63] [64] [65] [66] [67] .
Supplementary Note 5. BPD is nontoxic in the absence of light activation but does cause skin photosensitivity for 24 h and pain during laser treatment that can be managed by avoiding direct sunlight after treatment and by using analgesics during treatment 30 (e.g., no adverse events for treatment of PDAC 30 ).
Supplementary Note 6. The human metastatic PDAC AsPC1 cell line expresses RTKs involved in VEGF and MET signaling. AsPC1 cells express VEGR1 63 and MET 68 and possess multiple oncogenic mutations, including KRAS, p53 and p16 69 , associated with treatment-resistant PDAC tumours.
Supplementary Note 7.
Western blotting of pMET and total MET expression by AsPC1 cancer cells in vitro was performed to probe mechanisms of MET activation (phosphorylation) in response to BPD-PDT using scavengers of reactive oxygen species (ROS) as well as inhibitors of potential MET activation pathways. The results indicate that BPD-PDT photochemistry induces MET activation via epidermal growth factor receptor (EGFR; also expressed by AsPC1 cells 70 ) kinase activity (Fig. 4b ). First, a singlet oxygen-specific scavenger (singlet oxygen sensor green, SOSG 71, 72 ) strongly suppressed BPD-PDT-induced MET activation, whereas a hydroxyl radical-specific scavenger (mannitol 73 ) had a more modest but significant effect (Fig. 4b) . These results confirm that singlet oxygen and, to a lesser extent, radical production by BPDmediated photochemistry stimulate MET activation. This stress response to PDT corroborates prior reports of upregulated VEGF signalling in response to a variety of therapies 9-11 , including PDT 12,13 , and prior reports of upregulation of MET signalling in response to hypoxia 5, 7, 8, 16 . Here, tumour hypoxia in vivo resulting from PDT is the most obvious potential mechanism for MET up-regulation within the tumour milieu ( Supplementary Fig. 1) ; that is, multiple tumour cell types up-regulate MET and its ligand, hepatocyte growth factor/scatter factor, in response to tumour hypoxia (including cancer cells and endothelial cells 16 ). In fact, Gomer and colleagues previously demonstrated that Photofin-PDT induces increased tumour VEGF expression via HIF-1α-induced vegf gene transcription 12 (in similarity to the role of HIF-1α in inducing increased MET expression). Our group has shown increased tumour secreted VEGF levels in response to subcurative BPD-PDT in vivo 13 . In the same study, in vitro mechanistic studies of VEGF upregulation by cancer cells in response to BPD-PDT indicated activation of p38 mitogen-activated protein kinases (MAPK) and stress-activated protein kinase (c-Jun NH 2 -terminal kinase, JNK) independent of HIF-1α 13 . BPD-PDT is also known to induce tumour hypoxia via oxygen consumption during PDT and microvascular shutdown resulting from PDT 74, 75 . Therefore, BPD-PDT is likely to induce MET activation by multiple stress response pathways involving both cancer cells and stromal cells within the tumour microenvironment.
Second, we performed western blotting of pMET and total MET expression in the presence of biological inhibitors for known pathways of MET activation inspired by reports of MET transactivation via EGFR-MET cross-talk [76] [77] [78] [79] and ROS-dependent mechanisms involving EGFR and G protein-coupled receptors (GPCRs) 77 . A molecular inhibitor that specifically blocks EGFR kinase activity (AG1478) 77 significantly reduced BPD-PDT-induced MET activation (Fig. 4b) . In contrast, an inhibitor (bacterial toxin B 77 ) of the GTPase activity of NADPH oxidase (a downstream modulator of EGFR-kinase-independent-and GPCR-MET cross-talk 77 ) had no effect on MET activation. Collectively, these data indicate EGFR-kinase-dependent-mediated MET transactivation due to cancer cell stress responses to ROS generated during BPD-PDT. As already mentioned, hypoxia and other mechanisms involving tumour stromal cells also potentially play a role in PDT-induced MET expression and activation.
